GlassScriptPhysician profile
Tiffany Suzanne Davies
NPI 1386754133
$1,895.32
in general payments reported to CMS, 2019-2025
26 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $191 · 2021: $83.46 · 2022: $65.52 · 2023: $202 · 2024: $450 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.05 | 2022-2025 | Qulipta, Vraylar |
| Pfizer INC. | $252.27 | 2019-2025 | |
| Lilly USA, LLC | $174.05 | 2019-2025 | Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $116.78 | 2019-2023 | Arexvy |
| Kowa Pharmaceuticals America, INC. | $94.65 | 2019-2020 | |
| Therapeuticsmd, INC. | $93.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.43 | 2019-2025 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $55.50 | 2019 | |
| Exact Sciences Corporation | $53.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $52.67 | 2019-2020 | |
| Astellas Pharma US INC | $43.39 | 2020-2024 | Veozah |
| Gilead Sciences, INC. | $42.97 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $42.39 | 2019 | |
| Sanofi Pasteur INC. | $33.75 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.29 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $28.85 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.47 | 2025 | Caplyta |
| Hikma Pharmaceuticals USA | $22.76 | 2023 | Ryaltris, Mitigare |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2025 | |
| Sumitomo Pharma America, INC. | $21.24 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $20.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.35 | 2025 | |
| Amag Pharmaceuticals, INC. | $14.60 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Davies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.